The objective of this paper is to study the literature available concerning the dangers involved with sublingual immunotherapy and the use of inhibitors or β-blockers for angiotensin conversion enzymes (ACE). It also assesses variations between the sublingual immunotherapy (SLIT) tablets available in certain risk areas. In order to classify the publications read by peers using the following keywords, a PubMed literature scan was carried out: anaphylaxis, ACE inhibitor, β-blocker and sublocker immunotherapy. In patients who are taking ACE inhibitors or β-blockers simultaneously, minimum data are available about SLIT protection. The incidence of adverse effects among SLIT products seems similar.

The patient taking a β-blocker should be informed before starting SLIT by a risk-on-benefit discussion, although immediate denying of SLIT is not warranted to these patients.